Regeneron Pharmaceuticals, Inc.

Seqirus UK Limited

The University of Texas System

Novartis Ag

Synthetic Genomics, Inc.

Lawrence Livermore National Security, LLC

Glaxosmithkline Biologicals Sa

Synthetic Genomics Vaccines, Inc.

Peter W Mason

Philip R Dormitzer

William C Olson

Pirada Suphaphiphat

Christos Kyratsous

Michael Franti

Neil E Stahl

Heidi Trusheim

Bjoern Keiner

Alida Coppi

Raul Gomila

Ilya V Frolov

Paul D Hoeprich

Juerg Hunziker

Elena Frolova

Nicholas O Fischer

Craig D Blanchette

David Morrissey

Anders Lilja

Rebecca Loomis

Björn Keiner

Melissa Sackal

Andrew J Murphy

Dong Yu

Karolina Meagher

Francois Jean-Charles Natt

Brinda Prasad

Tomohiro Ishikawa

Stefania Crotta

Francois Natt

Jennifer Uhlendorff

Mikhail Matrosovich

Samuel Ho

Peter Fekkes

David Parker

Ivna De Souza

Pirada Allen

Daniel Gibson

Caitlin Jeanette Hagen

David Wentworth

Timothy Stockwell

Peter Shahinian

John Glass

François Jean-Charles Natt

Philip Ralph Dormitzer

Stephania Crotta

The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to Ebola virus glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing Ebola virus activity, thus providing a means of treating or preventing Ebola virus infection in humans. In some embodiments, the invention provides for use of one or more antibodies that bind to the Ebola virus for preventing viral attachment and/or entry into host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.

Human antibodies to ebola virus glycoprotein

Disclosed herein are methods for increasing protein yield and cellular productivity. Chemical agents facilitate host cell production of biological molecules to increase product yield.

Compositions and methods to increase production

The invention relates to platforms for delivery of herpes virus proteins to cells, particularly proteins that form complexes in vivo. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using such platforms permits the generation of broad and potent immune responses useful for vaccine development.

Antigen delivery platforms

The present invention provides antibodies that bind toHemolysin A toxin, and methods of use. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Hemolysin A. The antibodies of the invention are useful for inhibiting or neutralizing Hemolysin A activity, thus providing a means of preventing or treating a Hemolysin A-related disease or disorder such asinfection. In some embodiments, the antibodies of the present invention are used in treating at least one symptom or complication of ainfection.

Human antibodies toHemolysin A toxin

Human antibodies to Ebola virus glycoprotein

The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to ZIKV glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing ZIKV activity, thus providing a means of treating or preventing ZIKV infection in humans. In some embodiments, the invention provides for use of one or more antibodies that bind to the ZIKV for preventing viral attachment and/or entry into host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.

Anti-Zika virus antibodies and methods of use

This disclosure provides platforms for delivery of herpes virus proteins to cells, particularly proteins that form complexes in vivo. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using the disclosed platforms permits the generation of broad and potent immune responses useful for vaccine development.

The invention provides, inter alia, improved replicons and vectors encoding them, where the replicons provide sustained expression of an encoded protein. These replicons comprise flavivirus replicases and heterologous protein coding sequences, wherein the heterologous protein coding sequences are flanked by separation sequences for improved efficacy. These nucleic acids provided by the invention, including self-replicating RNAs provided by the invention, are useful in methods of protein expression, such as for vaccines (e.g., for methods of immunization), as well as expression of therapeutic proteins, such as antibodies (e.g., for methods of treatment).

Flavivirus replicons

Human antibodies tohemolysin A toxin

According to certain embodiments, the present disclosure provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds aspecies target antigen and a second antigen binding domain that binds a complement component. In certain embodiments, the bispecific antigen-binding molecules of the present disclosure are capable of binding to thespecies target antigen with an ECof about 10 nM or less, and/or are capable of promoting complement deposition on thespecies with an ECof about 10 nM. The antibodies of the disclosure are useful for treating diseases in which inhibition or reduction of the growth of aspecies is desired and/or therapeutically beneficial, for example, for treating staphylococcal infections including a skin infection, cellulitis, pneumonia, meningitis, urinary tract infection, toxic shock syndrome, endocarditis, osteomyelitis, bacteremia, or sepsis, or for preventing or treating ainfection that occurs as a result of a surgical procedure.

Bispecific antigen-binding molecules that bind atarget antigen and a complement component and uses thereof

New influenza donor strains for the production of reassortant influenza B viruses are provided.

Influenza virus reassortment

The invention provides various reverse genetics systems for producing segmented RNA viruses, wherein the systems do not require bacteria for propagation of all of their expression constructs.

Reverse genetics systems

New influenza donor strains for the production of reassortant influenza A viruses are provided.

Growing community of inventors

New York, NY, United States of America

Peter W Mason